Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients - PubMed (original) (raw)

Clinical Trial

. 2009 May;115(2):359-63.

doi: 10.1007/s10549-008-0128-9. Epub 2008 Jul 23.

Affiliations

• PMID: 18649131
• DOI: 10.1007/s10549-008-0128-9

Clinical Trial

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

T Byrski et al. Breast Cancer Res Treat. 2009 May.

Abstract

Background: Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant cisplatin, followed by mastectomy and conventional chemotherapy.

Methods: The excised breast tissue and lymph nodes were examined for the presence of residual disease.

Results: Pathologic complete response was observed in nine patients (90%).

Conclusions: Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are now warranted to determine the optimum treatment for this subgroup of breast cancer patients.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal